JSCPT 2025 – The 46th Annual Scientific Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics
We’re excited to participate in JSCPT 2025 in Tokyo, The 46th Annual Scientific Meeting of…
CertaraOctober 31, 2024
Why You Need an Integrated Development Plan
Learn about the Integrated Development Plan for successful drug development & its relation to the…
CertaraOctober 17, 2024
Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
CertaraSeptember 23, 2024
Resmetirom: A pioneering NASH clinical program
Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic…
CertaraAugust 23, 2024
Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
CertaraAugust 19, 2024
Medicines that matter: Biohaven’s Nurtec™ drug development journey
In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved…
CertaraAugust 15, 2024
Clinical Pharmacology & Model-Informed Drug Development Insights for Targeted Radiation Therapies
Targeted radiation therapies (TRT) deliver cytotoxic radiation selectively to tumors. In recent years, oncology drug…
CertaraMay 22, 2024
